Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: hypromellose; magnesium stearate; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - angielski - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mesalazine, quantity: 250 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; povidone; sodium carbonate; purified talc; titanium dioxide; iron oxide red; colloidal anhydrous silica; calcium stearate; glycine; iron oxide yellow; methacrylic acid copolymer; macrogol 6000; triethyl citrate - indications as at 12 september 1990: treatment of acute inflammatory large bowel disease. maintenance therapy of crohns colitis and ulcerative colitis in patients sensitive to sulfasalazine.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar i disorder: lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet or capsule or lithium citrate products [see adverse reactions (6)]. risk summary: lithium may cause harm when administered to a pregnant woman. early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for ebstein’s anomaly, with first trimester use of lithium. subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. there are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see clinical considerations] . published animal developmental and toxicity studies in mice and rats report an increased incidence of fetal mortality, decreas

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar i disorder: - treatment of acute manic and mixed episodes in patients 7 years and older [see clinical studies (14)] - maintenance treatment in patients 7 years and older [see clinical studies (14)] lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet  [see adverse reactions (6)] . risk summary lithium may cause harm when administered to a pregnant woman. early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for ebstein’s anomaly, with first trimester use of lithium. subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. there are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see cl